Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium

• Published in: Naunyn-Schmiedeberg's archives of pharmacology Vol. 386; no. 8; pp. 671 - 684
• Main Authors: Weninger, Sabine, De Maeyer, Joris H., Lefebvre, Romain A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-08-2013
• Subjects: 1-Methyl-3-isobutylxanthine - pharmacology; Animals; Atrial Function - physiology; Benzofurans - pharmacology; Biomedical and Life Sciences; Biomedicine; Calcium-Binding Proteins - physiology; Cyclic AMP - physiology; Cyclic GMP - physiology; Cyclic Nucleotide Phosphodiesterases, Type 3 - physiology; Cyclic Nucleotide Phosphodiesterases, Type 4 - physiology; Heart Atria; In Vitro Techniques; Male; Myocardial Contraction - physiology; Neurosciences; Original Article; Pharmacology/Toxicology; Phosphodiesterase Inhibitors - pharmacology; Phosphorylation; Receptors, Serotonin, 5-HT4 - physiology; Serotonin - pharmacology; Serotonin 5-HT4 Receptor Agonists - pharmacology; Swine; Troponin I - physiology; cGMP; receptor; 5-HT; Phosphodiesterases; cAMP; Pig atrium
• ISSN: 0028-1298; 1432-1912
• DOI: 10.1007/s00210-013-0855-2

Our objective was to investigate the role of phosphodiesterase (PDE)3 and PDE4 and cGMP in the control of cAMP metabolism and of phosphorylation of troponin I (TnI) and phospholamban (PLB) when 5-HT
4
receptors are activated in pig left atrium. Electrically paced porcine left atrial muscles, mounted in organ baths, received stimulators of particulate guanylyl cyclase (pGC) or soluble guanylyl cyclase (sGC) and/or specific PDE inhibitors followed by 5-HT or the 5-HT
4
receptor agonist prucalopride. Muscles were freeze-clamped at different moments of exposure to measure phosphorylation of the cAMP/protein kinase A targets TnI and PLB by immunoblotting and cAMP levels by enzyme immunoassay. Corresponding with the functional results, 5-HT only transiently increased cAMP content, but caused a less quickly declining phosphorylation of PLB and did not significantly change TnI phosphorylation. Under combined PDE3 and PDE4 inhibition, the 5-HT-induced increase in cAMP levels and PLB phosphorylation was enhanced and sustained, and TnI phosphorylation was now also increased. Responses to prucalopride per se and the influence thereupon of PDE3 and PDE4 inhibition were similar except that responses were generally smaller. Stimulation of pGC together with PDE4 inhibition increased 5-HT-induced PLB phosphorylation compared to 5-HT alone, consistent with functional responses. sGC stimulation hastened the fade of inotropic responses to 5-HT, while cAMP levels were not altered. PDE3 and PDE4 control the cAMP response to 5-HT
4
receptor activation, causing a dampening of downstream signalling. Stimulation of pGC is able to enhance inotropic responses to 5-HT by increasing cAMP levels, while sGC stimulation decreases contraction to 5-HT cAMP independently.